In a landmark move that ties drug pricing reform directly to patient access, Regeneron has agreed to lower U.S. drug prices for some Americans and will offer the first approved gene therapy for hearing loss at no cost to eligible patients. The announcement came Thursday from the White House, just hours after the Food and Drug Administration granted accelerated approval to the company’s groundbreaking treatment.
The therapy, called Otarmeni, targets an ultra-rare genetic mutation that prevents the body from producing a protein essential for hearing. In clinical trials, the gene therapy restored hearing in a small number of children who were born deaf. The treatment received expedited approval under the FDA’s National Priority Voucher program, signaling its potential as a transformative option for patients who previously depended solely on cochlear implants. Analysts at Piper Sandler estimate the therapy could generate peak sales of $130 million, though under the pricing agreement, eligible U.S. patients will receive it for free.
Regeneron is the latest drugmaker to strike a pricing deal under President Trump’s “most favored nation” initiative, which aims to tie U.S. drug prices to the lowest rates paid in other developed nations. The agreement also exempts Regeneron from tariffs for three years, including planned levies of up to 100% on some pharmaceutical products. According to CMS deputy administrator Chris Klomp, the Trump administration has now finalized 17 such deals with biotech and pharmaceutical companies, with more negotiations underway.
A New Model for Access and Innovation
For patients with this specific genetic form of hearing loss, Otarmeni represents more than a medical breakthrough. It offers a path to hearing without the need for surgical implants or lifelong device maintenance. The free access provision means that financial barriers will not stand in the way of families seeking this therapy. While the treatment currently addresses only a small subset of deaf children, researchers say the approval validates gene therapy as a viable approach for other forms of hereditary hearing loss.
Looking ahead, Regeneron plans to work with healthcare providers and insurers to identify eligible patients and ensure smooth access to the therapy. The broader pricing agreement signals a willingness among major drugmakers to engage with federal efforts to lower costs, even as the administration continues to push for more comprehensive reforms. For the children who stand to benefit, the combination of scientific progress and affordability offers a hopeful new chapter in hearing loss treatment.